Article · pages 77–78
Refractory Evans’ Syndrome : Therapeutic Options
Cite this article
Naveet Wig, Monica Gupta, Rohini Handa, Praveen Aggarwal. Refractory Evans’ Syndrome : Therapeutic Options. J Int Med Sci Acad. 2005;18(2):77–78.
Opening of the article
Some chronic immune-mediated hematological disorders in adults, such as autoimmune hemolytic anemia (AHA), idiopathic thrombocytopenic purpura (ITP) and autoimmune hemolytic anemia with thrombocytopenia (Evans’ syndrome) will achieve a prompt and last remission after corticosteroid treatment. Nevertheless, many patients will be resistant1. They might be requiring high dose corticosteroid therapy or other modalities of treatment such as intravenous high-dose immunoglobulins (frequent but transient improvement),2 suppression by chemotherapeutic durgs (about 50% response rate) and or splenectomy (50-70% complete or partial remissions).